Free PcMED Insider NewsletterClick here
Alerts Allergy And Immunology Cancer Screening Cardiology Cervical Cancer Screening Dermatology Diabetes Endocrine ENT Evidence Matters General Internal Medicine Genetics Geriatrics GI PcMED Connect GU Hematology ID Medical Legal Mental Health MSK Nephrology Neurology FAQs@PcMED PrEP Resource Center PrEP for Physicians PrEP for Patients Preventive Medicine Pulmonary Rheumatology Test Your Knowledge Vaccinations Women's Health Your Practice

Patient with Stable CVD: Rivaroxaban, Aspirin or Both to Prevent Recurrent Events?


  • Aspirin reduces risk of major CV events by 19% and CV death by 9% in those with CVD
    • 5 to 10% of patients will still have recurrent CV events
  • Eikelboom et al. (NEJM, 2017) assessed whether rivaroxaban, aspirin or both is most effective for secondary cardiovascular event prevention in those with stable atherosclerotic vascular disease


  • Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial
  • 602 centers in 33 countries
  • Double-blind randomized controlled (RCT) trial
  • Inclusion criteria: Coronary artery disease, peripheral arterial disease, or both
  • Participants were randomly assigned to 1 of 3 cohorts
    • Rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily)
    • Rivaroxaban (5 mg twice daily)
    • Aspirin (100 mg once daily)
  • Primary outcome
    • Composite of cardiovascular death, stroke, or myocardial infarction
  • The study was stopped short at 23 month follow-up, due to superiority of the rivaroxaban and aspirin group


  • Comparing to aspirin-alone group, the rivaroxaban-plus-aspirin group had
    • Fewer patients (4.1% vs 5.4%) with adverse cardiovascular events (hazard ratio [HR] 0.76; 95% CI 0.66 to 0.86; P<0.001)
    • More major bleeding events occurred (3.1% vs 1.9% HR 1.70; 95% CI 1.40 to 2.05; P<0.001)
  • Most major bleeding was into the gastrointestinal tract
  • There was no significant difference in intracranial bleeding, fatal bleeding or bleeding into a critical organ
  • There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group ([HR] 0.82; 95% CI 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025)
  • When comparing rivaroxaban-alone group than in the aspirin-alone group, there was no significant difference in primary outcome but there were more major bleeding events


  • Rivaroxaban-plus-aspirin had better cardiovascular outcomes compared to aspirin alone
  • Rivaroxaban alone did not impact outcomes and had more major bleeding events than aspirin alone

Learn More – Primary Sources:

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease